Company intelligence / Profile preview

Persica Pharmaceuticals

Canterbury, Kent, United Kingdompersicapharmaceuticals.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Positive Phase 1b clinical data for PP353 announced in March 2025. The trial met its primary endpoint and demonstrated statistically significant, clinically meaningful, and durable reduction in pain and disability in patients with chronic Low Back Pain with Modic Type 1 changes, with meaningful reductions in pain from 3 months up to at least 12 months[4][10].

Therapeutic areas: Rheumatology
Modalities: Small molecules (antibiotic formulation)
Industry: Biotech

Drug pipeline

1 asset

PP353

Beyond the preview

Go deeper on Persica Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Persica Pharmaceuticals.

Explore the full profile